Search Videos and More
ASCO 2026 Highlights Panel Discussion
Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Erica Mayer, MD, MPH; and Jennifer Ligibel, MD, discuss important breast cancer research presented at the 2026 ASCO Annual Meeting.2026 ASCO Breast Cancer Highlights: Food Access, Poverty, and MBC
Harold Burstein, MD, PhD, and Rachel Freedman, MD, MPH discuss the results of a new study looking at the impact of food access and poverty on patients with metastatic breast cancer. They also discuss the new Dana-Farber food pantry and patient navigators who help coordinate care.2026 ASCO Breast Cancer Highlights: PANKU-Breast02
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.2026 ASCO Breast Cancer Highlights: persevERA
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the persevERA trial and oral SERDS in metastatic breast cancer.2026 ASCO Breast Cancer Highlights: SENOMAC
Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.Dana-Farber Research Supports FDA Approval of New Therapy for “Double-Positive” Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director of International Strategic Initiatives at Dana-Farber Cancer Institute.ASCO26: Jennifer Ligibel, MD, BWEL
Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.Treatment Guideline: First-Line Treatment for Metastatic Triple-Negative Breast Cancer (TNBC)
The Breast Oncology Center held meetings to discuss recommendations regarding first-line treatment for patients with metastatic triple-negative breast cancer (TNBC).ADC Provides Patients with Better Results Even After Subsequent Therapy for Advanced Triple-Negative Breast Cancer
A shift in the way advanced triple-negative breast cancer is treated may be on the horizon with mounting evidence that moving sacituzumab govitecan, an antibody-drug conjugate (ADC), to the first line of treatment confers long-term benefit compared to standard therapy, including continued benefit even after subsequent therapy.Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
A new study from Dana-Farber Cancer Institute shows that cases of stage IV breast cancer, a common but largely difficult to treat disease, are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published today JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly, from 9.5 cases per 100,000 women in 2010 to 11.2 cases per 100,000 women in 2021. Stage IV, or de novo metastatic breast cancer, refers to cancer has already spread to distant organs at the time initial diagnosis.